CVS CEO defends pharmacy middlemen, accuses drugmakers of ‘monopolistic’ practices

CVS CEO defends pharmacy middlemen, accuses drugmakers of ‘monopolistic’ practices


David Joyner, a longtime CVS executive, speaks during a Senate Health, Education, Labor and Pensions Committee hearing in Washington, D.C., on May 10, 2023.

Al Drago | Bloomberg | Getty Images

CVS Health CEO David Joyner on Wednesday defended controversial pharmacy middlemen like his company’s Caremark unit, which are widely accused of inflating prescription medication prices, and instead accused manufacturers of “monopolistic tendencies” that keep drug costs high in the U.S. 

Joyner, who stepped into the role in October, spent much of his opening remarks on the company’s fourth-quarter earnings call discussing so-called pharmacy benefit managers, or PBMs. It was atypical for CVS’ quarterly call to begin that way, but comes at a time when lawmakers on both sides of the aisle and President Donald Trump have signaled interest in cracking down on PBMs. 

CVS owns Caremark, one of the nation’s three largest PBMs that collectively administer roughly 80% of prescriptions in the U.S.

Those middlemen negotiate rebates with drug manufacturers on behalf of insurers, create lists of medications known as formularies that are covered by insurance and reimburse pharmacies for prescriptions. But lawmakers and drugmakers alike argue that PBMs overcharge the plans they negotiate rebates for, underpay pharmacies and fail to pass on savings from those discounts to patients.

Joyner acknowledged that rising health-care costs in the U.S. are pressuring patients, employers and the federal government. He blamed factors such as increased patient utilization of services, rising health-care provider costs, labor shortages and “dramatic price hikes” for branded drugs. 

But he said PBMs like Caremark are “one of the most powerful forces helping to offset rising health care costs,” claiming that they are the only part of the drug supply chain solely focused on lowering costs. 

“Our work is a critical counterbalance to the monopolistic tendencies of drug manufacturers,” Joyner said. “This is why PBMs are needed and why manufacturers fight so hard to limit our capabilities.” 

He alleged that branded manufacturers added $21 billion in annual gross drug spending in the first three weeks of January through their price hikes, but did not cite where the figure is from. 

Joyner added that multiple economists have estimated that PBMs generate net value for the U.S. health-care system, more than $100 billion a year.

“No one has demonstrated more success than the PBMs of driving down drug prices,” he said.

However, the pharmaceutical industry and lawmakers argue that PBMs and insurers pocket those savings from negotiated rebates and discounts rather than passing them to patients.

In a statement on Wednesday, PhRMA, the nation’s largest lobbying group for the pharmaceutical industry said PBMs are “under intense, well-deserved scrutiny.” 

“Bipartisan state attorneys general, policymakers in both Congress and state legislatures and the FTC are all investigating these health care conglomerates,” a PhRMA spokesperson said. “They’ve all come to the same conclusion: PBMs are driving up costs and reducing access at the expense of patients, employers, and our health care system.”



Source

Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity
Health

Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity

Mounjaro manufactured by Eli Lilly and Company packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on April 9, 2024. Nurphoto | Nurphoto | Getty Images Eli Lilly on Thursday said its blockbuster diabetes drug Mounjaro showed heart health benefits in a late-stage trial directly comparing it to the company’s […]

Read More
Pandemic darlings Moderna, BioNTech are now on two different paths
Health

Pandemic darlings Moderna, BioNTech are now on two different paths

A researcher works in the lab at the Moderna Inc. headquarters in Cambridge, Massachusetts, US, on Tuesday, March 26, 2024.  Adam Glanzman | Bloomberg | Getty Images The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies are on different paths. Both Moderna and BioNTech helped pioneer mRNA, or […]

Read More
Healthy Returns: AstraZeneca CEO proposes some U.S. drug price cuts amid Trump pressure
Health

Healthy Returns: AstraZeneca CEO proposes some U.S. drug price cuts amid Trump pressure

The office building of international biopharmaceutical company AstraZeneca. Cfoto | Future Publishing | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. President Donald Trump has been pressuring pharmaceutical companies to lower U.S. drug […]

Read More